Helen Cicirello, | |
40845 Forest Glen Dr, Leesburg, VA 20175-6557 | |
(703) 327-0403 | |
Not Available |
Full Name | Helen Cicirello |
---|---|
Gender | Female |
Speciality | General Practice |
Location | 40845 Forest Glen Dr, Leesburg, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1720428428 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | D0052923 (Maryland) | Primary |
Mailing Address | Practice Location Address |
---|---|
Helen Cicirello, 40845 Forest Glen Dr, Leesburg, VA 20175-6557 Ph: () - | Helen Cicirello, 40845 Forest Glen Dr, Leesburg, VA 20175-6557 Ph: (703) 327-0403 |
News Archive
Clinical results from a Phase IIb study showed that MK-4305, Merck's investigational dual orexin receptor antagonist, was significantly more effective than placebo (p<0.005) in improving overall sleep efficiency at night one and at the end of week four in patients with primary insomnia. MK-4305 was generally well-tolerated in the study. Orexins are neuropeptides (chemical messengers) that are released by specialized neurons in the hypothalamus region of the brain and are believed to be an important regulator of the brain's sleep-wake process.
Hawthorn Pharmaceuticals, Inc. announced today an exclusive global licensing deal with CoPlex Therapeutics on hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer's and other neurodegenerative diseases.
"Access to affordable lifesaving medicines will be threatened where they are needed most - in parts of the developing world - if the U.S. insists on implementing restrictive intellectual property policies in the Trans-Pacific Partnership (TPP) trade agreement," states a press release from Doctors Without Borders.
Peptilogics, a development stage company utilizing its innovative peptide platform to treat multidrug-resistant bacterial infections, today announced it recently held a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration to discuss the regulatory pathway for the development of PLG0206 for the treatment of prosthetic joint infections.
Tobacco acts as a precipitating factor for headaches, specifically migraines. This is indicated in a study which shows that smokers have more migraine attacks and that smoking more than five cigarettes a day triggers this headache. The work has appeared in The Journal of Headache and Pain.
› Verified 5 days ago
Lindsay E Roach, D.O. General Practice Medicare: Medicare Enrolled Practice Location: 19500 Sandridge Way, Suite 110, Leesburg, VA 20176 Phone: 703-723-7337 Fax: 703-723-8278 |